Tags

Type your tag names separated by a space and hit enter

Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention.
Vaccine. 2000 Dec 08; 19 Suppl 1:S66-70.V

Abstract

Adults frequently develop eustachian tube dysfunction and middle ear pressure (MEP) abnormalities during natural and experimental influenza and human rhinovirus (HRV) infections. Oral rimantadine treatment did not reduce the otologic manifestations of experimental influenza in adults or natural influenza in children. However, intranasal zanamivir and oral oseltamivir significantly reduced MEP abnormalities during experimental influenza in adults, and oseltamivir treatment appears to reduce the likelihood of otitis media in children with acute influenza. Investigational anti-HRV agents, including intranasal tremacamra, intranasal AG7088, and oral pleconaril, warrant study in this regard. Depending on the virus, early antiviral therapy has the potential to impact the risk of otitis media following respiratory tract infections.

Authors+Show Affiliations

Department of Internal Medicine, University of Virginia School of Medicine, Box 800473, Charlottesville, VA 22908, USA. fgh@virginia.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11163466

Citation

Hayden, F G.. "Influenza Virus and Rhinovirus-related Otitis Media: Potential for Antiviral Intervention." Vaccine, vol. 19 Suppl 1, 2000, pp. S66-70.
Hayden FG. Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention. Vaccine. 2000;19 Suppl 1:S66-70.
Hayden, F. G. (2000). Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention. Vaccine, 19 Suppl 1, S66-70.
Hayden FG. Influenza Virus and Rhinovirus-related Otitis Media: Potential for Antiviral Intervention. Vaccine. 2000 Dec 8;19 Suppl 1:S66-70. PubMed PMID: 11163466.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention. A1 - Hayden,F G, PY - 2001/2/13/pubmed PY - 2001/7/6/medline PY - 2001/2/13/entrez SP - S66 EP - 70 JF - Vaccine JO - Vaccine VL - 19 Suppl 1 N2 - Adults frequently develop eustachian tube dysfunction and middle ear pressure (MEP) abnormalities during natural and experimental influenza and human rhinovirus (HRV) infections. Oral rimantadine treatment did not reduce the otologic manifestations of experimental influenza in adults or natural influenza in children. However, intranasal zanamivir and oral oseltamivir significantly reduced MEP abnormalities during experimental influenza in adults, and oseltamivir treatment appears to reduce the likelihood of otitis media in children with acute influenza. Investigational anti-HRV agents, including intranasal tremacamra, intranasal AG7088, and oral pleconaril, warrant study in this regard. Depending on the virus, early antiviral therapy has the potential to impact the risk of otitis media following respiratory tract infections. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/11163466/Influenza_virus_and_rhinovirus_related_otitis_media:_potential_for_antiviral_intervention_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264410X00002814 DB - PRIME DP - Unbound Medicine ER -